Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells
- PMID: 9699669
Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells
Abstract
It is generally believed that CTLs mature in lymphoid organs and then migrate into target tissues to execute their effector functions. This notion, however, is based on studies using antigens that are readily localized in the lymphoid tissue, such as viruses and allogeneic transplants. The site for maturation of CTLs for nonmetastatic tumors has not been determined. Because nonmetastatic tumor cells are not localized in lymphoid tissues, it is questionable whether such tumors are efficient inducers of antitumor CTLs. Here, we report that a nonmetastatic B7+ plasmacytoma induces strong effector CTL response. Thus, it is possible to induce CTLs with strong ex vivo CTL activity in the absence of tumor metastasis. In addition, a detailed kinetic analysis of CD8 T cell recruitment and maturation of CTL activity suggests that antitumor CTLs mature within the tumor rather than in the lymphoid tissues. Interestingly, despite B7-1 expression on tumor cells, induction of effector CTLs also requires costimulation by B7 on host antigen-presenting cells. These findings have important implications for tumor gene therapy and for understanding the mechanism of CTL induction in vivo.
Similar articles
-
Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.Cancer Gene Ther. 2000 Jun;7(6):861-9. doi: 10.1038/sj.cgt.7700193. Cancer Gene Ther. 2000. PMID: 10880016
-
A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha.J Immunol. 1997 Jul 1;159(1):360-8. J Immunol. 1997. PMID: 9200474
-
Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.Vaccine. 2008 Nov 5;26(47):5928-34. doi: 10.1016/j.vaccine.2008.08.051. Epub 2008 Sep 13. Vaccine. 2008. PMID: 18793691
-
Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells.Cancer Res. 2001 Feb 1;61(3):1107-12. Cancer Res. 2001. PMID: 11221840
-
The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.J Immunol. 1998 Sep 15;161(6):2740-5. J Immunol. 1998. PMID: 9743331
Cited by
-
Evolution of cell therapy for renal cell carcinoma.Mol Cancer. 2024 Jan 9;23(1):8. doi: 10.1186/s12943-023-01911-x. Mol Cancer. 2024. PMID: 38195534 Free PMC article. Review.
-
Treatment of lymphoma with adoptively transferred T cells.Expert Opin Biol Ther. 2009 Nov;9(11):1407-25. doi: 10.1517/14712590903260785. Expert Opin Biol Ther. 2009. PMID: 19723016 Free PMC article. Review.
-
B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo.J Exp Med. 2001 Nov 5;194(9):1339-48. doi: 10.1084/jem.194.9.1339. J Exp Med. 2001. PMID: 11696598 Free PMC article.
-
Genetic engineering of T cells for adoptive immunotherapy.Immunol Res. 2008;42(1-3):166-81. doi: 10.1007/s12026-008-8057-6. Immunol Res. 2008. PMID: 18841331 Free PMC article. Review.
-
Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.J Exp Med. 1999 Mar 1;189(5):811-20. doi: 10.1084/jem.189.5.811. J Exp Med. 1999. PMID: 10049945 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials